Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Nexavar Prescribers: Oncologists

Taral Patel, MD, Oncologist
Taral Patel, MD, Oncologist
Mid Ohio Oncology Hematology Inc.
February 19, 2008
improve Overall survival in prostate cancer
Analysis of: Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival (www.pipelinereview.com)
esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients'...
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
February 6, 2008
Sutent and NSCLca
Analysis of: Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer (jco.ascopubs.org)
Sutent is demonstrating some activity in Lung cancer Sutent is unique in this regard versus other TKIs ? I would focus on the FELT for obvious reasons
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
February 6, 2008
Hematide ; Just another ESA?
Analysis of: Takeda Doses First Patient in A U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia (www.pipelinereview.com)
Hematde is a new ESA with potential benefit over older ESAs hematide may look especially god coming off some of the recent FDA concerns abiut ESAs
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
February 6, 2008
The US not quite ready to throw in the iv pole
Analysis of: GlaxoSmithKline receives EMEA positive opinion for the approval of Hycamtin® (topotecan) hard capsules for the treatment of relapsed small cell lung cancer (www.pipelinereview.com)
New oral agents to replae previous iv meds will not likelty succeed in near future in US patient's are less compliant with oral meds, even for cancer
Eric Whitman, MD, Medical Director, Office of Grants and Research
Eric Whitman, MD, Medical Director, Office of Grants and Research
Atlantic Health System Inc
February 5, 2008
PEG Intron goes before ODAC in March 2008
Analysis of: FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma (www.pipelinereview.com)
Intron-A is currently the only FDA approved medicine to treat melanoma patients without active disease but at high risk for future recurrence. On March 12, 2008, the Oncology Drug Advisory Committee (ODAC) will discuss newly available data on the effectiveness and safety profile of PEG Intron, a longer...
Eric Whitman, MD, Medical Director, Office of Grants and Research
Eric Whitman, MD, Medical Director, Office of Grants and Research
Atlantic Health System Inc
January 23, 2008
Supreme Court makes correct decision on experimental drugs
Analysis of: No right to experimental drugs for dying patients: Supreme Court (news.yahoo.com)
The Supreme Court, in refusing to hear arguments in a case brought that would make it easier for patients to gain access to non-approved drugs, brought a legal end to the request of the Abigail Alliance. This suit would have circumvented the drug approval process while leading to patients receiving...
Eric Whitman, MD, Medical Director, Office of Grants and Research
Eric Whitman, MD, Medical Director, Office of Grants and Research
Atlantic Health System Inc
January 23, 2008
Judah Folkman was an amazing and inspirational medical pioneer
Analysis of: Famed Cancer Researcher Folkman Dies (ap.google.com)
The medical and scientific worlds lost a great man when Dr. Judah Folkman recently passed away. His work in anti-angiogenesis was very inspiring and created a whole new area of scientific research to fight cancer, which eventually led to new drugs and treatments, principally Avastin. Dr. Folkman was...
Eric Whitman, MD, Medical Director, Office of Grants and Research
Eric Whitman, MD, Medical Director, Office of Grants and Research
Atlantic Health System Inc
January 23, 2008
Patient to Patient doctor office ratings
Analysis of: WellPoint patients to review doctors online (www.healthcarefinancenews.com)
The announcement by Wellpoint that it will offer online evaluations of doctors and their offices is very interesting. Using a tool developed by Zagat's, patients in targest markets will be able to rate their physician "experience" on several unspecified factors, presumably dealing with things like doctor/office...
January 16, 2008
Sirolimus and mTOR inhibition
By a GLG Expert Contributor
Analysis of: Sirolimus Reduces Size of Angiomyolipoma Tumors (www.medscape.com)
Sirolimus has shown activity in shrinking benign tumors associated with tuberous sclerosis......opens the door for further exploration alone and combo in other mTOR driven disorders
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
January 14, 2008
Amgen's questionable future
Analysis of: Amgen's Outlook Brightens (online.wsj.com)
Amgen hit hard by recent ESA reimbursement requirements Amgen Has Neulasta, but is this a sure winner Amgen has no dynamite in near future

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 Next31 to 40 of 126

Analytics


Generated at 2009-01-07T19:00:58.307